Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis

Thorsten Derlin, Haefaa Alchalby, Peter Bannas, Azien Laqmani, Francis Ayuk, Ioanna Triviai, Hans Heinrich Kreipe, Frank M. Bengel, Nicolaus Kröger

Research output: Contribution to journalArticlepeer-review

Abstract

Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.

Original languageEnglish (US)
Pages (from-to)1556-1559
Number of pages4
JournalJournal of Nuclear Medicine
Volume57
Issue number10
DOIs
StatePublished - Oct 1 2016

Keywords

  • Allogeneic
  • F-FDG PET/CT
  • Myelofibrosis
  • Positron emission tomography
  • Stem cell transplantation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Serial <sup>18</sup>F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis'. Together they form a unique fingerprint.

Cite this